The Kava Anxiety Depression Spectrum Study (KADSS): A Randomized, Placebo-controlled Crossover Trial Using An Aqueous Extract Of Piper Methysticum
Notes for this study:
|Number of Subjects
||18-29, 30-44, 45-64
Over a period of 3 weeks active treatment (one week run in phase),16g of Kava standardized to 250mg of activa kavalactones daily (2/5ths in the morning and afternoon, 1/5th in the evening) as an aqueous extract was able to exert anxiolytic and anti-depressive actions in persons with at least one month of higher but stable anxiety levels.
No hepatotoxic signs noted via clinical assessment, liver enzymes not measured.